Genpharmasec Ltd
Incorporated in 1992, Generic Pharmasec
Ltd deals in pharmaceutical activities /services and trades in equity shares[1]
- Market Cap ₹ 58.1 Cr.
- Current Price ₹ 1.05
- High / Low ₹ 2.20 / 0.75
- Stock P/E 36.3
- Book Value ₹ 1.20
- Dividend Yield 0.00 %
- ROCE 2.58 %
- ROE 2.43 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.88 times its book value
- Company is expected to give good quarter
- Debtor days have improved from 111 to 76.3 days.
- Company's working capital requirements have reduced from 136 days to 61.1 days
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has low interest coverage ratio.
- Promoter holding is low: 30.0%
- Company has a low return on equity of 1.56% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.3.16 Cr.
- Promoter holding has decreased over last 3 years: -30.0%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Services Services Commercial Services & Supplies Trading & Distributors
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| 26 | 30 | 34 | 140 | |
| 25 | 30 | 33 | 139 | |
| Operating Profit | 0 | 0 | 0 | 1 |
| OPM % | 1% | 0% | 0% | 1% |
| 0 | 1 | 3 | 3 | |
| Interest | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 1 | 2 |
| Profit before tax | 0 | 0 | 2 | 1 |
| Tax % | -300% | 168% | 35% | 42% |
| 1 | -0 | 1 | 1 | |
| EPS in Rs | 0.02 | -0.00 | 0.02 | 0.03 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 76% |
| TTM: | 317% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 13% |
| TTM: | 30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | -28% |
| 3 Years: | -19% |
| 1 Year: | -48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 2% |
| Last Year: | 2% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 28 | 55 | 55 | 55 |
| Reserves | -12 | 9 | 10 | 11 |
| 3 | 4 | 5 | 35 | |
| 1 | 3 | 9 | 37 | |
| Total Liabilities | 20 | 71 | 80 | 138 |
| 0 | 1 | 8 | 41 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 1 | 19 | 19 | 2 |
| 19 | 51 | 53 | 95 | |
| Total Assets | 20 | 71 | 80 | 138 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| -3 | -3 | 3 | -18 | |
| 0 | -28 | -15 | 13 | |
| 3 | 48 | -1 | 4 | |
| Net Cash Flow | 0 | 17 | -14 | -0 |
| Free Cash Flow | -3 | -3 | -3 | -21 |
| CFO/OP | -1,277% | -7,275% | 3,825% | -1,357% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 82 | 109 | 148 | 76 |
| Inventory Days | 151 | 133 | 104 | 39 |
| Days Payable | 21 | 36 | 105 | 90 |
| Cash Conversion Cycle | 211 | 207 | 147 | 26 |
| Working Capital Days | 199 | 213 | 133 | 61 |
| ROCE % | 2% | 3% | 3% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Number of Permanent Employees employees ・Standalone data |
|
||||||
| Diagnostic Pharma Equipment Segment Revenue (Standalone) Rs. in Lakhs ・Standalone data |
|||||||
| Trading in Securities Segment Revenue (Standalone) Rs. in Lakhs ・Standalone data |
|||||||
| i-STAT Analyzers Imported (units) units ・Standalone data |
|||||||
| Simulators Imported (units) units ・Standalone data |
|||||||
| i-STAT Cartridges Imported (units) units ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
7 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no physical demat requests received.
-
Closure of Trading Window
26 Jun - Trading window closed from July 1, 2026 until 48 hours after Q1 FY27 results.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Genpharmasec filed FY2026 secretarial compliance report; PCS noted full compliance and no SEBI actions.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 May - Newspaper Publication of Audited Financial Result for the quarter and year ended 31st March, 2026.
-
Statement Of Deviation Or Variation In The Use Of Proceeds Of Rights Issue For The Quarter Ended 31St March, 2026.
21 May - Genpharmasec reports no deviation in ₹4,845.05 lakh rights issue proceeds for quarter ended March 31, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1]
GPL started as a manufacturer and trader of organic and inorganic chemicals, dyes and pigments and then shifted its business activities to buying, selling and distribution of pharmaceutical, medicinal and medicated preparations and also decided to deal in securities market. Currently, company is dealing in medical and diagnostics devices